

## **DECLARATION**

I, Jennifer Ann Geel, declare that this research report is my own, unaided work. It is submitted in partial fulfilment of the requirements for the degree of Master of Medicine in Paediatrics in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other university.

Signed on this \_\_\_\_ day of \_\_\_\_\_, 2016.

Supervisor:                      Professor Janet Poole

## **DEDICATION**

To Thandi, Tamai and Senzo.

## PRESENTATIONS

The data in this report has been presented, in part, in the following settings:

1. **Annual congress of the South African Children’s Cancer Study Group, Durban, 22-24 May 2009.**

“A review of 54 patients with germ cell tumours treated at Charlotte Maxeke Johannesburg Academic Hospital: a 25 year retrospective review”.

Oral presentation.

2. **SIOP (International Society of Paediatric Oncology) Africa conference, Cape Town, 21-23 March 2012.**

“Germ cell tumours in Johannesburg: A 28 year review.”

Oral presentation.

3. **Wits Paediatric Department weekly meeting, 4 April 2012.**

“What’s new in African Oncology?” (Including “Germ cell tumours in Johannesburg”)

Oral presentation.

4. **Kids Cancer and Care workshop, Johannesburg, 26 July 2012.**

“Germ cell tumours in Johannesburg: A 28 year review.”

Oral presentation.

## **ABSTRACT**

Germ cell tumours have a good prognosis if treated aggressively but the consequence of cure may be life-altering toxicity. Prolonged duration of symptoms is often thought to contribute to poor outcomes in patients with solid tumours.

### **Aims:**

To document incidence, survival rates, extent of treatment-related toxicity and to identify poor prognostic indicators in children with germ cell tumours treated at the Charlotte Maxeke Johannesburg Academic Hospital. A secondary aim was to determine which classification system had validity in this cohort.

### **Methods:**

A retrospective file review was conducted of children with germ cell tumours treated at the Charlotte Maxeke Johannesburg Academic Hospital over a 28 year period. Descriptive statistics were employed to document incidence, toxicity rates and outcomes. Kaplan-Meier estimations were performed to determine prognostic factors.

### **Results:**

Seventy five patients were identified, 17 with benign tumours, 56 with malignant tumours and two unknown. Chemotherapy was given to 48 patients, in whom 32 (67%) experienced significant myelotoxicity. Of the 41 patients treated with cisplatin, 34% developed clinically significant hearing impairment. Five patients developed renal tubular acidosis, and two developed chronic renal failure.

The only independent factor found to have prognostic significance was complete surgical excision. There was no correlation between prolonged duration of disease-specific symptoms and poor outcome. The classification of patients according to the IGCCC system does not appear to correlate closely with determinations of prognosis, in comparison with conventional staging systems.

All patients who relapsed did so in the first 3 years after diagnosis. The 3 year overall survival rate was 77.8%. There were no recorded cases of secondary malignancies or chemotherapy-induced infertility.

## **Conclusion**

Complete surgical excision is vital for survival. Transient myelotoxicity and permanent hearing impairment are common when protocols incorporating cisplatin are used. Survival rates are acceptable for a middle-income country. Every effort should be made to preserve the good survival rate while decreasing toxicity.

## **THANKS AND ACKNOWLEDGEMENTS**

Daynia Ballot

Kate Bennett

Piet Becker

Vic Davies

Katherine Eyal

Bernard Goodwin

Cecil Levy

Sarah Mazengera

Rina Nortje

Janet Poole

Rosemarie Schwyzer

Frances Williams

## TABLE OF CONTENTS

	<b>Page</b>
Declaration	ii
Dedication	iii
Presentations	iv
Abstract	v
Acknowledgements	vii
Table of contents	viii
Abbreviations	xii
List of tables	xiii
List of figures	xiii
	<b>Page</b>
<b>Chapter 1: BACKGROUND</b>	
1.1 The setting	1
1.2 Brief overview of germ cell tumours	1
1.3 Relevance of this group of tumours	2
1.4 Purpose of auditing this cohort of patients	2
1.5 Classification system	4
1.6 Epidemiology	6
1.7 Known prognostic factors	6

1.7.1	Lactate dehydrogenase	7
1.7.2	Specific tumour markers	7
1.7.3	The example of sacrococcygeal tumours	8
1.8	Risk group stratification	9
1.9	Modalities of treatment	10
1.10	Early effects of treatment	12
1.11	Late effects of treatment according to site of tumour	12
1.11.1	Brain tumours	13
1.11.2	Mediastinal tumours	13
1.11.3	Abdominal tumours	13
1.11.4	Gonadal tumours	13
1.12	Late effects of treatment according to treatment modality	14
1.12.1	Chemotherapy	14
1.12.2	Radiation	14
1.13	Long term follow-up	15
1.14	Relapse	15
<b>Chapter 2:</b>	<b>AIMS OF THE STUDY</b>	<b>16</b>
<b>Chapter 3:</b>	<b>MATERIALS AND METHODS</b>	<b>17</b>
3.1	Study design	17
3.2	Study site	17
3.3	Study period	17
3.4	Study sample	17
3.5	Study method and data collection	17

3.6	Data analysis	18
3.7	Ethics	19
<b>Chapter 4:</b>	<b>RESULTS</b>	<b>20</b>
4.1	Study population	20
4.1.1	Age	20
4.1.2	HIV status	20
4.1.3	Sex	20
4.1.4	Race	21
4.1.5	Predisposing conditions	21
4.2	Duration of symptoms	21
4.3	Distribution of tumours	22
4.3.1	Distribution of tumours by malignant elements	22
4.3.2	Distribution of tumours by anatomy and histological elements	23
4.3.3	Distribution of tumours by primary site	24
4.4	Treatment	25
4.4.1	Chemotherapy	25
4.4.2	Radiation therapy	26
4.5	Survival rate	26
4.6	Causes of death	27
4.7	Relapse	28
4.8	Early toxicity	28
4.8.1	Myelotoxicity	28
4.8.2	Hearing loss	29
4.8.3	Renal dysfunction	29
4.8.4	Other adverse events	29
4.9	Late toxicity	30
4.9.1	Second malignant neoplasms	30

4.9.2	Effects on fertility	30
4.10	Long-term follow-up	30
4.11	Prognostic factors	30
<b>Chapter 5:</b>	<b>DISCUSSION</b>	<b>33</b>
5.1	Demographics	33
5.2	HIV infection rate	34
5.3	Predisposing conditions	34
5.4	Tumour site and histology	34
5.5	Staging and prognostic classification systems	35
5.6	Delays in diagnosis	36
5.7	Survival rate	37
5.8	Causes of death	37
5.9	Toxicity rates	38
5.10	Follow-up	40
5.11	Limitations of the study	40
<b>Chapter 6:</b>	<b>RECOMMENDATIONS</b>	<b>42</b>
<b>Chapter 7:</b>	<b>CONCLUSION</b>	<b>43</b>
<b>Appendix A</b>	Data capture sheet	44
<b>Appendix B</b>	Chemotherapy protocols	46
<b>Appendix C</b>	Grades of myelotoxicity	47
<b>Appendix D</b>	St Jude Children’s Research Hospital staging system for germ cell tumours	48
<b>Appendix E</b>	Staging system used by Children’s Oncology Group GCT trials	49
<b>Appendix F</b>	International Germ Cell Consensus Classification	51
<b>Appendix G</b>	Plagiarism report	52
<b>Appendix H</b>	Wits Human Research Ethics Committee clearance certificate	53
<b>REFERENCES</b>		<b>54</b>

## ABBREVIATIONS

$\alpha$ -FP	alpha fetoprotein
BEP	bleomycin, etoposide, cisplatin (modified protocol includes vinblastine)
$\beta$ -hCG	beta human chorionic gonadotrophin
CMJAH	Charlotte Maxeke Johannesburg Academic Hospital
CNS	central nervous system
COG	Children's Oncology Group
EFS	event free survival
FIGO	International Federation of Gynecology and Obstetrics
GCSF	granulocyte colony stimulating factor
GCT	germ cell tumour
HIC	high income countries
ICE	ifosfamide, carboplatin, etoposide
IGCCC	International Germ Cell Consensus Classification
LDH	lactate dehydrogenase
LMIC	low and middle income countries
LTFU	lost to follow up
JEB	carboplatin, etoposide, bleomycin
POU	paediatric oncology unit
RCT	randomised controlled trial
SIOP	Société Internationale de Oncologie Paediatrique
SMN	second malignant neoplasm
OS	overall survival
UKCCSG	United Kingdom Children's Cancer Study Group
VEC	vincristine, etoposide, carboplatin
YST	yolk sac tumour

## LIST OF TABLES

Table 1.	Modified Dehner classification of germ cell tumours	5
Table 2:	Distribution of tumours by malignant elements	22
Table 3:	Distribution of GCTS by anatomy and histological elements	23
Table 4:	Myelotoxicity associated with the different chemotherapy regimens	28
Table 5:	Malignant extracranial germ cell tumours. Conventional staging	31
Table 6.	Malignant extracranial germ cell tumours. Staging according to the International Germ Cell Consensus Classification	31
Table 7:	Log Rank (Mantell-Cox) analysis of significance of various parameters in prognostication	32

## LIST OF FIGURES

Figure 1:	Race of paediatric patients with GCTS at CMJAH, 1983-2011	21
Figure 2:	Distribution of tumours by anatomical site.	24
Figure 3:	Kaplan-Meier survival curve analysis for malignant germ cell tumours	26
Figure 4:	Causes of death	27